NCT06193525 - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Breast Cancer

Interventions

DRUG

Talazoparib

Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.

Trial Locations (3)

RECRUITING

Leiden University Medical Center, Leiden

RECRUITING

Erasmus Medical Center, Rotterdam

RECRUITING

Groningen University Medical Center, Groningen